Copertina

Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Manuel Barreiro‐de Acosta, Iago Rodríguez‐Lago
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing
di: Tomohiro Fukuda, et al.
Pubblicazione: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision?
di: L. A. A. P. Derikx, et al.
Pubblicazione: (2024)

Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
di: María Chaparro, et al.
Pubblicazione: (2024)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
di: Giammarco Mocci, et al.
Pubblicazione: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis‐A delicate balance of efficacy and safety
di: Shintaro Sagami, et al.
Pubblicazione: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively?
di: David Laharie
Pubblicazione: (2024)

Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply
di: Rocío Ferreiro‐Iglesias, et al.
Pubblicazione: (2024)

Editorial: Extending upadacitinib induction dosing in ulcerative colitis—A delicate balance of efficacy and safety. Author's reply
di: Remo Panaccione
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study
di: Merle Claßen, et al.
Pubblicazione: (2024)

A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis
di: Anthony Croft, et al.
Pubblicazione: (2024)

Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
di: Shintaro Akiyama, et al.
Pubblicazione: (2024)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
di: María José García, et al.
Pubblicazione: (2024)

Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply
di: Vibeke Strande, et al.
Pubblicazione: (2024)

Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people
di: Shuyao Song, et al.
Pubblicazione: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis
di: Fang Yan, et al.
Pubblicazione: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
di: David Bergman, et al.
Pubblicazione: (2024)

Drug‐induced liver injury from selective androgen receptor modulators, anabolic‐androgenic steroids and bodybuilding supplements in Australia
di: Emily Nash, et al.
Pubblicazione: (2024)

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
di: Rie Louise Møller Nordestgaard, et al.
Pubblicazione: (2024)

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
di: María José Casanova, et al.
Pubblicazione: (2025)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
di: Konstantinos Arvanitakis, et al.
Pubblicazione: (2024)

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply
di: Philip Vutien, et al.
Pubblicazione: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
di: Ayesha Shah, et al.
Pubblicazione: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
di: C. M. Fernández‐Rodríguez, et al.
Pubblicazione: (2024)

Editorial: Heads or Tails in the Treatment of Functional Dyspepsia—Does the Side of the Coin Matter?
di: Cedric Van de Bruaene, et al.
Pubblicazione: (2025)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
di: Ahmed B. Bayoumy, et al.
Pubblicazione: (2025)

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?
di: Maryam Zafer, et al.
Pubblicazione: (2024)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
di: Stephanie A. Vuijk, et al.
Pubblicazione: (2024)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
di: Cristina Rubín de Célix, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
di: Louise J. M. Alferink, et al.
Pubblicazione: (2024)

Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?
di: Luciano Revelli, et al.
Pubblicazione: (2024)

Editorial: To Stop or Not to Stop, Is It Still a Question? Authors' Reply
di: Jeongkuk Seo, et al.
Pubblicazione: (2024)

Editorial: Quantity is important!
di: Chee‐Kiat Tan
Pubblicazione: (2024)

Editorial: Beyond DNA Suppression: HBV RNA as a Predictor of Hepatocarcinogenesis
di: Toshifumi Tada
Pubblicazione: (2025)

Editorial: Gene Silencing Therapy for a New Era of Pancreatitis Prevention
di: Maxim S. Petrov
Pubblicazione: (2026)

Editorial: Plants against animals
di: Einar S. Björnsson
Pubblicazione: (2024)

Editorial: Terlipressin Induced Bradycardia
di: Nancy Reau, et al.
Pubblicazione: (2025)

Editorial: Distinct Challenges of Paediatric From Adult‐Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children
di: Alessandro Molinaro, et al.
Pubblicazione: (2024)